Overview

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Pediatric Subjects

Status:
Not yet recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of MYOBLOC for the Treatment of Chronic Sialorrhea in Pediatric Subjects.
Phase:
Phase 3
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.
Collaborator:
Solstice Neurosciences
Treatments:
Botulinum Toxins, Type A
rimabotulinumtoxinB